^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    VeriStrat®

    Company:
    Biodesix
    Type:
    Laboratory Developed Test
    Related tests:
    Evidence Level:
    Sensitive: B - Late Trials

    [CDKN2A negative-Squamous Cell Carcinoma of Head and Neck-afatinib]

    Source:
    Ann Oncol
    Test:

    VeriStrat®

    Title:
    Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer
    Excerpt:
    Subgroups of HNSCC patients who may achieve increased benefit from afatinib were identified based on prespecified tumor biomarkers (p16-negative, EGFR-amplified, HER3-low, PTEN-high).
    DOI:
    10.1093/annonc/mdx344
    Trial ID:
    LUX-Head&Neck 1
    Evidence Level:
    Sensitive: B - Late Trials

    [ERBB3-L-Squamous Cell Carcinoma of Head and Neck-afatinib]

    Source:
    Ann Oncol
    Test:

    VeriStrat®

    Title:
    Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer
    Excerpt:
    Subgroups of HNSCC patients who may achieve increased benefit from afatinib were identified based on prespecified tumor biomarkers (p16-negative, EGFR-amplified, HER3-low, PTEN-high).
    DOI:
    10.1093/annonc/mdx344
    Trial ID:
    LUX-Head&Neck 1
    Evidence Level:
    Sensitive: B - Late Trials

    [EGFR amplification-Squamous Cell Carcinoma of Head and Neck-afatinib]

    Source:
    Ann Oncol
    Test:

    VeriStrat®

    Title:
    Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer
    Excerpt:
    Subgroups of HNSCC patients who may achieve increased benefit from afatinib were identified based on prespecified tumor biomarkers (p16-negative, EGFR-amplified, HER3-low, PTEN-high).
    DOI:
    10.1093/annonc/mdx344
    Trial ID:
    LUX-Head&Neck 1
    Evidence Level:
    Sensitive: B - Late Trials

    [PTEN overexpression-Squamous Cell Carcinoma of Head and Neck-afatinib]

    Source:
    Ann Oncol
    Test:

    VeriStrat®

    Title:
    Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer
    Excerpt:
    Subgroups of HNSCC patients who may achieve increased benefit from afatinib were identified based on prespecified tumor biomarkers (p16-negative, EGFR-amplified, HER3-low, PTEN-high).
    DOI:
    10.1093/annonc/mdx344
    Trial ID:
    LUX-Head&Neck 1